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Abstract
Background: Biology, biomedicine and healthcare have become data-driven enterprises, where scientists and
clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-
related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow
aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses
on key elements to record experiments for therapy development. Specifically, we describe the experiments
performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a
therapy tested in a phase I clinical trial.
Findings: We introduce the Guidelines for Information About Therapy Experiments (GIATE), a minimum
information checklist creating a consistent framework to transparently report the purpose, methods and results of
the therapeutic experiments. A discussion on the scope, design and structure of the guidelines is presented,
together with a description of the intended audience. We also present complementary resources such as a
classification scheme, and two alternative ways of creating GIATE information: an electronic lab notebook and a
simple spreadsheet-based format. Finally, we use GIATE to record the details of the phase I clinical trial of CHT-25
for patients with refractory lymphomas. The benefits of using GIATE for this experiment are discussed.
Conclusions: While data standards are being developed to facilitate data sharing and integration in various
aspects of experimental medicine, such as genomics and clinical data, no previous work focused on therapy
development. We propose a checklist for therapy experiments and demonstrate its use in the
131Iodine labeled
CHT-25 chimeric antibody cancer therapy. As future work, we will expand the set of GIATE tools to continue to
encourage its use by cancer researchers, and we will engineer an ontology to annotate GIATE elements and
facilitate unambiguous interpretation and data integration.
Background
Recording experimental data
Recording and reporting experiments – including their
context, design, methods and results – in an unambigu-
ous manner is crucial for the advancement of biological
and biomedical research. Systematic reporting enables
data sharing and reuse, thereby avoiding repetition and
inefficient use of resources. Unambiguous data record-
ing allows for well-grounded comparisons and aggrega-
tion of experimental results. Analysis of the aggregated
data as a large dataset is more likely to produce statisti-
cally significant results. It is also expected to support
new hypothesis testing, simpler and better systematic
reviews and meta-analyses. Moreover, the data could be
used for teaching and training purposes [1]. In sum-
mary, the description of experiments should avoid dif-
ferent interpretations, and be presented in a way that
allows for sharing and integration.
Standardization initiatives for biological, biomedical and
health research
The development and use of guidelines containing key
information required to describe different kinds of bio-
logical and biomedical data are becoming widespread.
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to the Minimum Information About a Microarray
Experiment (MIAME) has been successfully adopted by
the transcriptomics community. Many journals [2] and
funders require the use of MIAME and it has been
implemented in some microarray databases (such as
ArrayExpress [3], the Gene Expression Omnibus (GEO)
[4] and the Center for Information Biology gene
EXpression (CIBEX) database [5]). Minimum informa-
tion (MI) checklists, in general, advocate reporting trans-
parency, better access to the data and support for
effective quality assessment [6]. They have been shown
to boost the value of the data produced in experiments
and related publications, by encouraging more transpar-
ency and improving the access to the data and its qual-
ity assessment [6].
The Minimum Information for Biological and Biome-
dical Investigations (MIBBI) [7] project coordinates the
development of these guidelines or checklists across the
different biological sciences domains. In order to pro-
vide improved access to these minimum information
checklists, MIBBI maintains a web-based portal with
summary information, links and complementary infor-
mation about them. The extra resources include data
formats, controlled vocabularies, ontologies, tools and
databases. Additionally, MIBBI coordinates the develop-
ment and harmonization of the MI specifications. This
coordination and harmonization process is important so
that integration of data complying with different MI
specifications is possible. Data integration is fundamen-
tal for secondary use of the data [6].
The EQUATOR [8] (Enhancing the QUAlity and
Transparency Of health Research) network is an inter-
national initiative looking to improve the quality of
reporting of clinical data for health research [9]. The
network promotes transparency and accurate reporting
by providing online resources and training for different
stakeholders. These include developers of reporting
guidelines, authors of research reports, journal editors
and peer reviewers [9,10].
The existence of both the MIBBI and EQUATOR pro-
jects demonstrates a perception that checklists are bene-
ficial to biomedical and health research. Some initial
studies have aimed at determining whether the adoption
of checklists proves beneficial [9]. Plint et al.[ 1 1 ]a n d
Smidt et al. [12] have looked at the impact of journal
support for checklists on the quality of publications (e.g.
completeness and transparency), indicating better qual-
ity in both cases, but with room for further improve-
ment. Plint et al. [11] present a systematic review of
studies that either a) compared journals that adopted
the CONSORT checklist against those that did not, b)
compared CONSORT adopters before and after the
checklist publication, or c) a combination of the
previous two cases. On the other hand, Smidt et al. [12]
analyse publications before and after thechecklist was
published. Other study has shown the link between a
Surgical Safety Checklist and the improvement of the
death rate [13,14], by analysing the data before and after
the introduction of the checklist.
Minimum information specifications or checklists
[6,15], therefore, refer to the metadata, or ‘data about
the data’, describing an experiment’sc o n t e x t ,d e s i g n ,
methods and results. To ensure that this information is
consistently reported, it is necessary to provide a unify-
i n gd a t af o r m a t .I nt h ec a s eo fm i c r o a r r a ye x p e r i m e n t s ,
the Microarray Gene Expression Data (MGED) society
first developed the MicroArray Gene Expression Mark-
up Language (MAGE-ML) [16] to accompany the
MIAME standard and enable the exchange of data
between laboratories and public databases. However,
MAGE-ML is too complex and not practical for labora-
tories without a dedicated bioinformatics support team.
Thus, a subsequent development resulted in a simple
s p r e a d s h e e t - b a s e df o r m a tc a l l e dM i c r o A r r a ya n dG e n e
Expression TABular (MAGE-TAB) [17]. MAGE-TAB
represents primary data and experimental metadata for
microarray investigations using spreadsheets. MAGE-
TAB is used by biologists for data collection, annotation,
and exchange between tools and databases, including
submissions to public repositories. Brazma [18] states
that, despite the popularity of the MIAME checklist, the
complementary MAGE-TAB format has not been as
successful within the community, having a low rate of
adoption.
To ensure that the data are interpreted in an unam-
biguous way, checklists and formats must be accompa-
nied by controlled vocabularies or ontologies. A
controlled vocabulary is a list of terms, each associated
with a clear definition that makes it distinct and unam-
biguous. Maintenance of the vocabulary (i.e. additions,
deletions, changes) is controlled. An ontology, on the
other hand, is a formal representation (i.e. with a logical
foundation) of the knowledge in a particular domain as
a set of concepts and their relationships. An ontology
provides greater interoperability than a controlled voca-
bulary. Continuing with the examples from the microar-
ray community, the MGED society also produced an
ontology based on the MIAME guidelines – the MGED
ontology [19,20] (MO) – that defines unambiguous
terms for the annotation of experiments; i.e. considering
the elements specified in the checklist.
Thus, the three basic components of a reporting struc-
ture are [6,15]:
￿ Minimum information (MI) specifications or
checklists
￿ Data formats: capturing MI in standard, non-pro-
prietary formats
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biguous, standard terms
In summary, the checklists indicate what should be
reported, the data standards specify the format or syntax
to be used, and the terminologies or ontologies ensure
that the meaning (or semantics)o ft h ed i f f e r e n te l e -
ments is unambiguous.
Recording therapy experiments
Therapy development involves activities ranging from
target discovery, the design of a therapeutic agent,
through to investigations of the effects of the agent in
molecular, cellular, animal and clinical models. Conse-
quently, therapy development involves interpreting and
integrating information from heterogeneous domains.
While communities within the biological, biomedical
and health research fields have developed guidelines to
report various experimental data, none have specifically
addressed therapy development. As in other areas of
biomedical research [21], publications about therapy
experiments often describe the data using free text or
static tables in different formats, and might lack some of
the information required to understand the experiment
in detail.
A standard for therapy experiments would bring
together different types of information, using, where
possible, existing standards corresponding to the rele-
vant sub-domains. The linkage of data from each sub-
domain would produce a unified view of the different
stages of therapy development. The immediate advan-
tages of utilising a standard for this linkage are the
avoidance of misinterpretations and repetition of time
consuming tasks, as well as the minimisation of the risk
to early phase clinical trials due to missing or misinter-
preted data.
In this paper, we describe the Guidelines for Informa-
tion About Therapy Experiments (GIATE) as a consis-
tent information framework for linking diverse data
types that can be applied to all the major types of ther-
apy. Using GIATE, complex data sets can be linked to
facilitate the understanding of the therapeutic system as
a whole, contributing to optimise the efficiency and
safety in the development of new treatments. One objec-
tive of the GIATE framework is to improve the commu-
nication between basic and clinical research by relating
data from both ends of the development spectrum.
Thus, with this translational medicine approach, we
expect that more therapeutic insights may be derived
from new scientific information.
GIATE originated from a collaboration among mem-
bers of the Antibody Society [22], who worked at identi-
fying the main elements that should be recorded for
antibody therapy experiments [23]. Initially, GIATE was
represented as a set of Common Data Elements (CDEs),
as per the ISO/IEC 11179 metadata registries’ standard
[24]. The objective of this representation was to allow
integration with the terminologies and data provided by
the cancer Biomedical Informatics Grid
® (caBIG
®) infra-
structure [25,26], whose metadata registry is ISO/IEC
11179-based [27].
At a later stage, GIATE was extended to support other
therapeutic approaches [28], while focusing on the
importance and necessity of sharing data and data stan-
dards as required precursors of effective data sharing.
A d d i t i o n a l l y ,[ 2 9 ]s h o w e dh o wG I A T Ee n a b l e st h e
establishment of a knowledge trail from molecular
experiments to clinical trials, reflecting the steps of ther-
apy development. This was exemplified with the key
information elements for the Antibody-Directed Enzyme
Prodrug Therapy (ADEPT) therapy, including informa-
tion about the molecular target, therapeutic agents and
experiments performed in molecular, cellular, animal
and clinical models.
In this paper, we review and extend previous GIATE
developments. The extension of previous work includes
making GIATE objectives, scope, audience, design and
structure explicit. As regards GIATE structure, we iden-
tify the modules that compose GIATE. We also intro-
duce an extended GIATE checklist and spreadsheet-
based data format. Finally, we consider a particular can-
cer therapy approach as a use case (CHT-25), and this
is made available in GIATE structured spreadsheets.
Results and discussion
The GIATE reporting guidelines
GIATE (Guidelines for Information About Therapy
Experiments) is a set of guidelines for the key informa-
tion that should be reported about a therapy experi-
m e n t ,s ot h a ti tc a nb ep r o p e r ly understood, analysed
and reproduced.
Objectives
The objectives of the development of GIATE are as
follows:
￿ To provide a consistent information framework for
reporting therapy experiments in a transparent way
￿ To support efficient data-sharing of therapy experi-
ments’ methods and results
￿ To guide the description of therapy experiments,
enabling reproducibility, data reuse and re-purposing to
avoid duplicated effort, support comparisons between
experiments and increase the quality of the data
￿ To facilitate the integration of data coming from
more than one experiment in a machine-processable
way
￿ To allow for the possibility of obtaining aggregated
and new knowledge coming from the statistical analysis
of the data or mining of the aggregated information
(data and knowledge mining)
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holders to use the GIATE guidelines
￿ To facilitate semantic publication of therapy experi-
ments [30]
Scope
The scope of the GIATE guidelines is therapy experi-
ments, such as small molecules targeting molecular
pathways, engineered protein therapeutics, radio-immu-
notherapy, anti-vascular therapies, cellular therapies and
others. For the design and development of new and
improved therapies, it is cru c i a lt ob ea b l et oi n t e g r a t e
laboratory and clinical data. Thus, GIATE aims at pro-
viding an information framework to record the proper-
ties of the target, the agent and models, the therapy
investigation design, context and outcomes from the dif-
ferent studies.
Audience
These guidelines are mainly intended for use by
researchers designing a therapy experiment, to assist
them in collecting consistent data elements. Moreover,
they are intended to act as a reference in order to form
a coherent description of an experiment.
G I A T Ei sa l s oi n t e n d e dt ob eu s e db yjournal editors
and referees to help confirm that certain data elements
are uniformly presented in publications, and that their
interpretation is unambiguous, allowing for the verifica-
tion of the conclusions obtained.
Other potential beneficiaries of GIATE are the com-
munities that regulate and fund therapy experiments.
Within these communities, the Antibody Society [22]
has adopted the GIATE specification.
Additionally, GIATE is intended to be used for educa-
tional or training purposes: we endorse the view that
good research reporting habits should be introduced as
early as possible in a researcher’s career, to both stu-
dents and young researchers [9]. The structure of
GIATE presents the main properties of a therapy in a
consistent manner, which facilitates the understanding
of the therapy’s strategy, intentions and achieved
outcomes.
To benefit the different stakeholders, the GIATE pro-
ject aims at providing tools that will help in making the
extra effort of recording the experiments minimal and
worthwhile.
Design
G I A T E[ 3 1 ]i sp a r to ft h eM I B B I( M i n i m u mI n f o r m a -
tion for Biological and Biomedical Investigations) Con-
sortium [6,32]. Following the MIBBI design guidelines
used in other specifications [21,33], GIATE does not
intend to provide an exhaustive list of data required or
resulting from a therapy experiment. Instead, GIATE
balances the trade-off between the depth of information
required to record an experiment and the burden for
the researcher to produce and maintain this metadata
(or data about the data). Thus, the compromise between
sufficiency and practicability [33] has been considered in
GIATE’s development.
GIATE is structured as a set of modules, most of
which are specific to therapy experiments. Others, such
as the citation module, are generic and could be reused
within other guidelines. GIATE establishes the relation-
ship between its constituent modules. Each module
encapsulates the information related to a specific sub-
domain of therapy development. A modular design
guarantees that changes in a specific module will be
local and will not affect the guidelines and tools related
to other modules.
In comparison to guidelines that focus on specific
assay results, such as MIAME [18,34] or the Minimum
Information About Cellular Assay (MIACA) [35],
GIATE can be considered a ’meta-guideline’ because it
deals with high-level information from studies ranging
from the lab to the clinic. These other guidelines form
independent modules in GIATE, where appropriate.
Users are therefore presented with domain specific
guidelines if a higher level of detail is required to record
any aspect of their data. GIATE, then, is the ‘glue’ link-
ing diverse data to support translational research.
Another important feature of GIATE is that it is not
static. As with other checklists such as the Minimum
Information for Molecular Interaction experiments
(MIMIx) [21], it is expected that through the increasing
participation of the therapy community, GIATE will
evolve to reflect the changing requirements in the con-
text of a rapidly evolving therapeutics science. In this
paper we present specific versions of the GIATE check-
list and its related tools.
Structure
Figure 1 depicts a schematic view of the main compo-
nents of a therapy experiment, which are classified into
the GIATE core modules, supplementary modules and
links to external resources.
As per MIBBI guidelines, we consider the distinction
between Investigation, Study, and Assay. An investiga-
tion refers to ‘a self-contained unit of scientific enquiry’
[6] that is characterised by an hypothesis or objective
and a design, which is defined by the relationship
between one or more studies and assays.C o r eG I A T E
modules can be seen as a tree, including the therapeutic
investigation description at the root and more specific
studies including data on the therapy development at
the branches and leaves.
The main GIATE module is the Therapeutic Investiga-
tion, whose design is determined by the Therapeutic
Target and the Therapeutic Agent.I nt u r n ,t h eAgent
may be composed of one or more Components.
Figure 2 presents the internal structure of the Thera-
peutic Investigation module, with sub-modules
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Supplementary modules for citations about the target,
agent and components are also included, together with
links to external resources.
The studies are represented by the different Models
(see Figure 1) as each investigation may be applied to
one or more models. Model types include: Molecular,
Cellular, Animal (or pre-clinical) and Clinical.Ap a r t i -
cular Investigation m a yh a v eb e e na p p l i e do n l yt os o m e
of the models, for example to Cellular and Molecular
models but not to the rest. Progress made from bench-
side to bed-side can be tracked with the information in
GIATE element types. Common characteristics of all
the models are grouped into a generic Model module.
Each of these models may have one or more assays. For
example, a cellular model might contain information
about cellular assays, which are reported to the MIACA
checklist. When describing each of the modules, we dis-
cuss some of the relevant guidelines that researchers
should consider for each sub-domain. Figure 3 shows
some of the relevant guidelines per each module.
In addition to the GIATE core modules, we designed
am o d u l er e p r e s e n t i n gCitations,w h i c hi sd e s c r i b e di n
more detail when the GIATE checklist is introduced. In
the future, other supplementary modules such as Ima-
ging will be considered, given their role in therapy devel-
opment [36].
GIATE Classification scheme
As described in the background section, GIATE was
initially designed as a set of Common Data Elements
(CDEs), as per the ISO/IEC 11179 standard for metadata
Figure 1 GIATE modules This figure presents a schematic representation of the main modules of a therapy experiment: Therapeutic
Investigation and the four Models in which the therapeutic can be applied (zero or more of each category including Molecular,
Cellular, Animal and Clinical models). A supplementary model with metadata about citations is also depicted, as well as links to external
databases.
Figure 2 GIATE Therapeutic Investigation This figure shows the
main elements of a Therapeutic Investigation: the Target and
the Agent. Moreover, the Agent may contain one or more
components. Each of the elements might be associated with one or
more Citation modules and linked to external databases.
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that it maintains, but also the rules, operations and pro-
cedures that it uses to maintain its content. According
to the registry standard, the set of CDEs determines a
classification scheme,a st h e ya r eg r o u p e db yt h ec o m -
mon characteristic of representing GIATE information.
Figure 4 shows a schematic view of the components of
the ISO/IEC 11179 standard [37]. A data element is the
basic container for data and it might represent an
abstraction or an entity from some system. Data ele-
ments have both representational and semantic compo-
nents [37]. In turn, the semantics involve two aspects:
symbolic and contextual types. The contextual semantics
comprise a data element concept, which indicates the
types and characteristics of objects for which data are
recorded [37]. The symbolic semantics come from a
conceptual domain, which is a set of categories (enum-
erated or expressed with a description) representing the
permissible or allowable values in a value domain. The
representational level includes the data element itself as
well as one or more associated value domains, specifying
the set of permitted values [37]. We note that the meta-
data registry standard includes in a single model con-
ceptual and representational aspects. The content to
report is determined by a data element as an Object-
Class,aProperty and a Value Domain.
Thus, a CDE involves simultaneously the three aspects
of a reporting structure as seen before: what to record,
how to record it, what is the meaning of the information
recorded. Additionally, what to record (checklist) and
h o wt od oi t( f o r m a t )a r ei n t e r t w i n e db e t w e e nt h ec o n -
ceptual and representational levels.
Figure 3 GIATE and its relationship with other minimum information guidelines and ontologies 5. This figure shows some of the
ontologies and other minimum information guidelines that are relevant for each of the modules in GIATE. The relationships shown between
each module and ontologies (in green) and MIBBI guidelines (in purple) are just presented as examples of potential ontologies/guidelines that
might be considered when using GIATE.
Figure 4 GIATE ISO 11179 Metadata Registry Components This
diagram is an overview model of the ISO/IEC 11179 metadata
registry standard. The figure is based on Figure 4 from [37].
González-Beltrán et al. BMC Research Notes 2012, 5:10
http://www.biomedcentral.com/1756-0500/5/10
Page 6 of 14When identifying the sets of CDEs for a particular
domain, it is recommended to reuse existing CDEs as
much as possible, as this results in increasing interoper-
ability of new data resources based on the new classifi-
cation scheme with existing data resources. When
developing the GIATE checklist we found that making
this effort to reuse CDEs could impose constraints on
the content of the key elements. For example, when
dealing with the animal model some of the existing
CDEs had an ObjectClass related to Animal while others
had an ObjectClass related to Organism: Animal Cancer
Model Phenotype Description java.lang.String and
Organism Species Name java.lang.String [38]. However,
when specifying what to record, having to use these two
CDEs might be confusing, as in both cases we are refer-
ring to properties of the Organism used in the Animal
Model.
In this paper, then, we present the key information
elements independently of the CDEs, which can be asso-
ciated a later stage. Thus, we divide GIATE in the three
levels as determined by a reporting structure, and pre-
sent the content to be reported independently of any
data format.
GIATE Notebook
One of the tools developed to support GIATE is the
GIATE Notebook-a piece of software that can be used
as an electronic lab book to capture data on therapy
experiments. The interface is composed of three panels:
one for the GIATE elements, another one containing
the CDE details showing associated terminology for
each element and the third for data entry. The data pro-
duced with the GIATE Notebook can be exported as an
eXtensible Markup Language (XML) document or in
Portable Document Format (PDF).
More details on the GIATE notebook and its use for
the ADEPT therapeutic investigation applied to an ani-
mal model [39] were presented in [28].
GIATE Checklist
We have developed a checklist with the key information
that should be recorded about therapy experiments. The
checklist main modules are as in Figure 1. In this paper,
we will briefly describe each of the modules and will
show the module concerning the clinical model in more
detail, as this is the main component of the use case
presented at section 2.3. The complete GIATE checklist
file, version 0.1, is available as Additional file 1.
Therapeutic investigation module This module
involves some general information such as the goal and
a brief description of the experiment, with an indication
of the therapy type (e.g. antibody therapy), and a set of
keywords and experimental factors. It also includes two
sub-modules specifying the target and the agent, includ-
ing possible components and their properties.
For the target, agent and components, it is required to
specify their identifiers as available in public databases.
As in other minimum information specifications, such
as MIMIx [21], we emphasise that ambiguous molecule
identifiers, such as gene names, should be avoided.
Instead, GIATE recommends that all molecules be iden-
tified by a database accession number from a public
database (for example, the database resources of the
National Center for Biotechnology Information [40]).
A database accession number identifies a unique
molecule. In the case of a gene, giving its database
accession number not only indicates its name but also
the species from which the gene originated, which can-
not be known by providing the gene name alone. It is
noted that the annotations of proteins may change over
time, for example when the coding sequence prediction
programmes are updated [21]. These changes may inva-
lidate the mapping of specific sequence positions such
as those where binding domains are described [21].
Thus, as in MIMIx [21], an optional version number of
the molecule or of the database is recommended in
GIATE.
Table 1 presents the recommended public databases
to identify each type of molecule. It is observed that
therapeutic targets, agents or their components may not
be present in public databases at the time of the experi-
ment. In those cases, it is recommended to include as
much information about the molecule as possible, such
as its generic name, synonyms and references to publi-
cations describing it.
It is expected that the Therapeutic Investigation mod-
ule will be included when reporting any kind of therapy
experiment, regardless of which models are included.
Molecular model module This module describes the
experiments that study the strength of bonds between
the target molecule and agent (or between components
o ft h ea g e n t )a sw e l la st h ed i s t r i b u t i o no ft h ea g e n t .
Bond strengths are described in terms of affinity and
avidity. Distribution is described in terms of concentra-
tion, volume and stability. This module also includes
information about dose regimens.
A relevant minimum information specification that
could be use to complement this module is MIMIx [21].
Table 1 Molecules Identification This table summarises
the recommended public databases to be used for
molecules identification
Molecules Identification
Proteins UniProt [41-43] or RefSeq [44,45]
Genes Ensembl [46] or Entrez Gene [47,48]
Chemical Entities PubChem [49] or ChEBI [50,51]
Drugs DrugBank [52,53]
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at the cellular level. GIATE recommends describing the
genetic and epigenetic profiles of the cell lines in terms
of:
￿ The germline and somatic mutations
￿ Epigenetic silencing
￿ Gene expression fold changes.
This module is also used to record the distribution of
both target and agent, in relation to specific dose regi-
mens and the concentration and duration of drug expo-
sure required for efficacy and toxicity.
Pre-Clinical (or Animal) model module This module
lists information elements relevant to therapy experi-
ments in animal models. Some key elements are also
present in the cellular model: e.g. genetic and epigenetic
profile, and target distribution study. GIATE recom-
mends recording details about the organism (its species
name, phenotype description and developmental stage),
as well as pharmacokinetics, pharmacodynamics and
therapy outcomes in relation to different dose regimens.
Clinical model module For a clinical model, GIATE
recommends recording information such as the name of
the trial, its phase, the number of patients, their medical
conditions (associated, if possible, with an accession
identifier from SNOMED CT or the Systematized
NOmenclature of MEDicine-Clinical Terms [54]), the
type of the trial (e.g. phase, single or multiple centre,
open label, non-comparative dose escalation), its end-
points and objectives as well as eligibility and exclusion
criteria used for participant selection.
Considering endpoints, i.e. measurements that can
demonstrate the clinical benefit of the trial, some possi-
ble values are: overall survival (OS), time to tumour pro-
gression (TTP), objective overall response (ORR),
complete response (CR) and time to treatment failure
(TTF) [55].
Safety is a very important factor in the clinical model.
In particular, for first-in-human trials, both the safe
starting dose and higher dose levels or dose escalation
criteria is paramount. Usually, the dose selection is
based on specifically designed preclinical pharmacology
and toxicology studies, ex vivo or in vitro experiments
with human and animal cells and pharmacokinetics/
pharmacodynamics (PK/PD) studies [56]. Thus, the dose
selection is a clear example of how the previous mod-
ules in GIATE influence, and could be the source of the
data, for the clinical model. However, the binding affi-
nity of agent to target may differ across species and it is
necessary to consider the relative potency between ani-
mal and humans [56]. There is evidence where life-
threatening events directly related to the pharmacology
of monoclonal antibodies were not predicted from pre-
clinical toxicology studies (e.g. in the TGN1412 case)
[56]. As a consequence, guidelines to explore the full
pharmacological dose/concentration-response curve
were introduced together with the concepts of Minimal
Anticipated Biological Effect Level (MABEL) and No
Observed Adverse Effects Level (NOAEL) [56]. Hence,
GIATE recommends recording NOAEL and MABEL
information.
As in the animal model, GIATE recommends to
include the genetic and epigenetic profiles, target distri-
bution, PK/PD studies, and therapy outcomes.
If applicable, GIATE recommends considering existing
guidelines on health research for the clinical model.
For example, if the clinical model is a randomised
controlled trial (RCT), the Consolidated Standards of
Reporting Trials (CONSORT) should be used [57]. The
CONSORT statement is part of the EQUATOR network
presented in Section 1. CONSORT was developed by a
group of scientists and editors aiming at improving the
quality of reporting of RCTs, as overwhelming evidence
showed that the quality of RCT reporting was not opti-
mal [57]. The CONSORT statement consists of a check-
list indicating the main information elements to include
when reporting an RCT and a flow diagram [57].
Citation module GIATE specifies a citation module.
This is a supplementary module, as it is not specifically
related to a therapy development. A citation is a refer-
ence to another entity.
When referring to bibliographic citations, the refer-
ence points to a publication such as a journal article, a
book, a chapter, or a web page [58]. On the other hand,
data citations consider reference to associated data.
Our Citation module is generic and allows to link any
module or any of its elements to an entity, which can be
a journal article, a database, a database record, a web
page, a multimedia item, and so on. In Figure 1 we
show how the Therapeutic Investigation or each of the
Models can be linked to one or more citations.
GIATE-TAB: a simple spreadsheet based format for cancer
therapy experiment data
We have developed a simple spreadsheet-based format
for recording information about GIATE: GIATE TABu-
lar (GIATE-TAB). The advantages of using a spread-
sheet are two-fold: researchers are usually familiar with
this format and it gives them some freedom on how
they report the experiment. We believe that this is parti-
cularly important when the guidelines are in the first
phases of development, as this will allow scientists to
add information elements they consider relevant and
feed back so that these can be incorporated in subse-
quent versions.
GIATE-TAB includes not only metadata about the
therapeutic investigation, as described in the GIATE
checklist, but also some generic input metadata for
each module (see Figure 5). This metadata is based on
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users to identify for each module: the title of the
resource, a description, the creators, publishers and
contributors to the metadata, the metadata source,
date of creation, issuance and modification. These
metadata elements are fundamental as they allow
backtracking from the metadata to its sources. This is
known as the provenance for each of the modules.
The WC3 Incubator Group on Provenance define ‘the
sources of information, such as entities and processes,
involved in producing or delivering an artifact’ [60].
Their final report emphasises that the information
about provenance of information is fundamental to
establish if the data are to be trusted, to determine
the way in which they can be integrated with other
data and to support accreditation of the data origina-
tors in case of re-use [60].
The GIATE-TAB spreadsheet is provided as the Addi-
tional file 2.
In the near future, we expect to use tools such as the
ISA Software Suite [61]. ISA stands for Investigation/
S t u d y / A s s a ya n dt h eI S Ai n f r a s t r u c t u r e[ 6 1 ]i sag e n -
eral-purpose format and freely available desktop soft-
ware suite designed enabling curation of experimental
metadata and supporting minimum information stan-
dards and, where available, submission to public data
repositories. In particular, we will use the ISAconfigura-
tor tool [61] to create a GIATE configuration, using the
fields from the GIATE checklist. The GIATE configura-
tion file will be used by biologists or cancer researchers
to compile therapeutic investigation metadata using the
ISAcreator tool [61].
Use case: CHT-25 therapy
In this section, we present the use of the GIATE check-
list and GIATE-TAB for a therapy experiment described
in [62]. This experiment consisted of a Phase I trial of
radio-immunotherapy with
131Iodine Chimeric Antibody
(CHT25) to the IL-2 receptor in refractory lymphomas
[62]. The main source of the GIATE metadata was the
paper itself [62] and it was complemented with informa-
tion available in the clinical trial protocol and data pro-
vided by the authors. The completed GIATE-TAB file is
available as Additional file 3. As future work, we expect
to link the GIATE-TAB information to the raw trial
data. As CHT-25 is an ongoing study, we expect to re-
use the recorded GIATE elements as the study pro-
gresses and show how data can be integrated to facili-
tate further comparison and analysis.
Therapeutic investigation module
In the therapeutic investigation module (see Figure 6),
we have included general information about the
Figure 5 Investigation Schematic view of GIATE-TAB, which apart from the information on GIATE guidelines includes provenance data
at different levels of abstraction.
González-Beltrán et al. BMC Research Notes 2012, 5:10
http://www.biomedcentral.com/1756-0500/5/10
Page 9 of 14investigation: its goals, description, therapy type, experi-
mental factors and its conclusions.
Additionally, the target (CD25, Interleukin-2 receptor
subunit alpha), the agent (
131Iodine labeled CHT-25 chi-
meric antibody) and its two components (CHT-25 and
131Iodine) are specified. CHT25 is a chimeric monoclo-
nal antibody with murine variable regions and human
constant regions. CHT25 was radiolabelled with
131I, an
appropriate radionuclide for radio-immunotherapy as it
has b emission length of 0.8 mm and g emissions for
imaging purposes.
The citation module is used to link to papers describ-
ing properties of the target [63,64] and the method used
for the radioiodination of the antibody in the agent [65],
as referred in the original paper.
Molecular module
The affinity of binding between CHT25 and IL-2 recep-
tor is approximately that of IL-2 itself [62]. Previous
results refer to the unlabeled antibody which has been
used to prevent transplant rejection in renal patients.
An alternative unlabeled antibody has shown short-term
benefit in human T-cell lymphotrophic virus-associated
lymphoma, where the IL-2 forms part of a growth path-
way [62].
Cellular module
No cell lines studies exist for this therapy.
Animal module
There is no suitable representative animal model for
131I-CHT25. While Rhesus monkeys contain the same
IL-2R epitope, they are not suitable for therapy studies.
Toxicology for
131I-CHT25 has not been performed in
pre-clinical models either [62].
Thus, within the reporting for the CHT-25 study the
animal model includes comments about these facts.
Clinical module
The first section of the clinical model in GIATE-TAB
includes general information about it:
Figure 6 GIATE-TAB for CHT-25, Therapeutic Investigation Section of GIATE-TAB for CHT-25 corresponding to the Therapeutic
Investigation. The figure shows the elements of the investigation design for the CHT-25 therapy, the properties of the target molecule, the
agent molecule and its two components. Moreover, we also show a citation module related to the radiolabeling method used for the
131Iodine
component.
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such as evaluation of the toxicity, pharmacokinetics,
immunogenicity and anti-tumour activity of CHT25
￿ The number of patients, with description of the elig-
ibility and exclusion criteria: the study involved 14
patients who had CD25 positive lymphomas (Hodgkin
lymphoma, HTLV associated adult T-cell lymphoma
and peripheral T-cell lymphoma) in which standard
therapies had failed or were not tolerated [62].
￿ The study design or type, which in this case is single
centre, open label, non-randomized, multiple dose esca-
lation phase I trial.
￿ The conclusions: it was found that CHT25 has an
important clinical activity in CD25 positive refractory
lymphomas; it is relatively non-immunogenic with low
toxicity at a non-myeloablative dose. Further studies are
required to assess clinical effectiveness and these will be
carried out in a Phase 2 trial.
This sub-module on General Information is linked to
a citation module referring to the article [62].
For this therapy, information was included about indi-
vidual patients. Elements referring to the type of lym-
phoma and treatment history are considered, including
treatments such as chemotherapy, Autologous Stem Cell
Transplant (ASCT), radiotherapy, time since last ther-
apy, stage at therapy, and bone marrow involvement.
The sub-modules for genetic/epigenetic profile, target
distribution and pharmacodynamics are not relevant for
this particular investigation, and that is indicated in
GIATE-TAB.
Information for the dose regimen is included for the
investigation and for individual patients. The study con-
sisted of a dose escalation using a standard dose of 10
mg of CHT25 antibody, with escalation of the radioac-
tive iodine from 370Mbq/m
2 to 2960Mbq/m
2.
CHT-25 was administered to 13 patients in 24 cycles.
The dose limiting toxicity was determined at 2960 Mbq/
m
2 with grade 4 myelosuppression in one patient. The
patient failed stem cell re-engraftment and died of infec-
tion. The dose was reduced to obtain the maximum tol-
erated dose and 3 patients were treated at 1200 Mbq/m
2
with recruitment completing at 1480 Mbq/m
2.O t h e r
toxicities were mild.
A distribution study was performed to analyse radioac-
tivity uptake in target and non-target tissues. The main
conclusions are summarised in GIATE-TAB.
Details of the radiation dosimetry study are also
included. It is noted that this GIATE sub-module is
only relevant for radioimmunotherapy experiments.
GIATE-TAB also includes information about Pharma-
cokinetics (PK) studies,i . e .h o wad r u go rs u b s t a n c ei s
absorbed, distributed, processed and eliminated in ani-
mals and humans. In order to study the PK for
131I in
the CHT-25 investigation, blood samples were taken
into EDTA blood tubes at the following time points,
when possible: 1, 3, 6 and 24 h, then on day 2, 3, 6 and
9. The data presented in the paper [62] has been tran-
scribed to GIATE-TAB including general parameters (e.
g. median clearance for 50% and 90%) as well as per
patient information. The latter comes from a tabular
representation in the paper, giving the parameters of the
PK interpolation curves per patient. The curve is either
monoexponential, described by a single parameter, or
biexponential, described by two parameters.
Finally, a sub-module indicating the outcome is also
included, at the investigation and patient levels. Ele-
ments included are best response, Common Toxicity
Adverse Events Grade and survival status. As the Che-
son criteria [66] were used to classify the patient
response (best response), e.g. as stable disease (SD),
complete response (CR), partial response (PR) and so
on. A citation module referring to Cheson et al. ‘sa r t i -
cle [66] was linked to the outcome study sub-module.
Benefits of using GIATE for CHT-25
In this section, we indicate how GIATE has contributed
to knowledge about CHT-25 and how having the data
elements in the GIATE-TAB spreadsheet will help in
understanding the different components of the therapy
as well as facilitate secondary use of the data.
Firstly, the spreadsheet provides an overall view of
the CHT-25 therapeutic investigation,w h i c hh i g h -
lights the main points and their relationships. This pro-
cess is simplified by the spreadsheet in comparison with
the more time consuming task of reading the paper, the
protocol, and if necessary, contacting the authors of the
trial.
Secondly, the spreadsheet provides links to external
resources that are available neither in the scientific arti-
cle nor in the protocol. For example, the GIATE-TAB
format for CHT-25 makes clear that the therapeutic tar-
get is CD25-Interleukin-2 receptor subunit alpha, acces-
sible in UniProt (at http://www.uniprot.org/uniprot/
P01589, version number 130). The specific link to Uni-
Prot allows users to uniquely identify the molecule that
is mentioned in the paper. Thus, scientists wanting to
analyse the CHT-25 trial could navigate to extra infor-
mation about the CD25 molecule. Similarly, additional
information about the agent component CHT-25 is
accessible through the DrugBank database (at http://
www.drugbank.ca/drugs/DB00074).
Thirdly, the paper provides static information pre-
sented in diagrams and tables. On the other hand, the
GIATE-TAB for CHT-25 makes re-use of the informa-
tion in a dynamic fashion. For example, while the
pharmacokinetics analysis is available in the paper as
Table 1[62], the figures cannot be immediately used to
generate the interpolation curves. By having the data in
GIATE-TAB, it is possible to generate these curves
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pharmacokinetics data.
Finally, having the CHT-25 data in GIATE-TAB format
facilitates answering queries about the therapeutic
investigation much easier than having to go through the
whole paper or protocol. For example, GIATE-TAB allows
users to identify quickly what were the studies performed
for the CHT-25 therapy and compare the Cheson score
for the outcome of each patient at a glance. Additionally,
GIATE-TAB is a step towards answering queries about
therapeutic investigations in a machine processable
way. As part of our future work, we intend to build a ther-
apeutic investigations knowledge base, which will support
to retrieve this kind of information.
Conclusions
The development of therapy experiments involves activ-
ities ranging from target discovery to therapeutic design,
and experiments to study the therapeutic approach per-
formed in molecular, cellular, animal and clinical mod-
els. Interpreting this heterogeneous information in an
unambiguous fashion is fundamental to draw new con-
clusions that interrelate data from the different models.
GIATE has been presented as a set of guidelines divided
into several modules, each dealing with one of the
aspects or stages of the therapy development process.
We have introduced the key elements of each of the
modules and a use case for the CHT-25 therapy, focus-
ing on collating GIATE information about the target,
the agent and the molecular model and the phase I trial.
As demonstrated in other areas of biological and biome-
dical research, producing a guideline to record experi-
ments is the first step towards being able to report them
transparently, compare them and integrate data coming
from different experiments. We discussed the benefits of
describing the CHT-25 therapy following GIATE.
As future work, we will develop an ontology asso-
ciated with GIATE to facilitate both data annotation
and data integration, by making the recorded elements
unambiguous. Additionally, we will provide a machine-
processable format to store information elements and
facilitate automated data integration. This format will
support building a knowledge base of therapeutic inves-
tigations with rich querying capabilities and links to
other relevant data repositories.
We welcome feedback from the scientific community
to help improve our proposal for recording therapy
experiments. The GIATE project’se m a i la d d r e s si sg i a -
te@ucl.ac.uk.
Additional material
Additional file 1: The GIATE checklist version 0.1 is included as an
additional file. It is noted that the file contains links to terms belonging
to different ontologies. Some of these terms belong to the NCI thesaurus
and were extracted from the GIATE classification scheme. These terms
are provided as a guideline but are not considered part of the GIATE
checklist. The terms will be exploited during the development of the
GIATE ontology. – GIATE checklist version 0.1.
Additional file 2: The second additional file is the GIATE-TAB
spreadsheet to be used in conjunction with the GIATE checklist,
when compiling metadata about therapy experiments. – GIATE-TAB
spreadsheet.
Additional file 3: The third additional file is the GIATE-TAB
spreadsheet completed with metadata about the CHT-25 phase 1
trial. – GIATE-TAB spreadsheet for the CHT-25 cancer therapy.
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